Fitzgerald Kevin Joseph
SEC CIK 1886431 · EDGAR
BoughtSold
Most active insiders at OVID, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ALEXANDER MARGARET A. | Pres, CEO, Dir | — | $16.9K |
| 2 | Rona Jeffrey A | CBFO | — | $12.4K |
| 3 | Fitzgerald Kevin Joseph | Dir | — | — |
| 4 | Carter Charles Ross | CFO | — | — |
| 5 | Takeda Pharmaceuticals U.S.A., Inc. | 10% | — | — |
| 6 | Friedman Bart | Dir | — | — |
| 7 | LEVIN JEREMY M | Executive COB, Dir | — | — |
| 8 | PAPADOPOULOS STELIOS | Dir | — | — |
Transactions 27
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-09 17:15 | 2026-04-07 | OVID | Ovid Therapeutics Inc. | Fitzgerald Kevin Joseph | Dir | A - Grant | $2.56 | +17.6K | 17.6K | New | +$45.0K | |
| M | 2026-03-06 | 2026-03-04+ | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $323.54 | -1,291 | 21.7K | -6% | -$417.7K |
| DM | 2026-03-04 | 2026-03-02+ | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $323.62 | -3,250 | 21.9K | -13% | -$1.05M |
| D | 2026-03-04 | 2026-03-02 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +3,688 | 25.1K | +17% | $0 |
| 2026-02-25 | 2026-02-23 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +158 | 21.4K | +0.7% | $0 | |
| 2026-02-17 | 2026-02-12 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +4,000 | 25.3K | +19% | $0 | |
| M | 2026-02-17 | 2026-02-13+ | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $321.24 | -4,000 | 21.3K | -16% | -$1.28M |
| 2026-01-14 | 2026-01-11 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +3,800 | 25.1K | +18% | $0 | |
| M | 2026-01-14 | 2026-01-12+ | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $367.37 | -3,800 | 21.4K | -15% | -$1.40M |
| DM | 2025-11-19 | 2025-11-17 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale+OE | $452.18 | -12.1K | 21.3K | -36% | -$5.48M |
| D | 2025-11-19 | 2025-11-17 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | M - OptEx | $119.13 | +8,161 | 33.4K | +32% | +$972.2K |
| M | 2025-10-03 | 2025-10-02 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $452.05 | -2,441 | 25.2K | -9% | -$1.10M |
| M | 2025-10-03 | 2025-10-01 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +4,953 | 24.8K | +25% | $0 |
| M | 2025-08-19 | 2025-08-18 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $453.27 | -1,396 | 23.0K | -6% | -$632.8K |
| 2025-08-19 | 2025-08-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +2,851 | 24.1K | +13% | $0 | |
| 2025-07-02 | 2025-07-01 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +7,763 | 21.3K | +57% | $0 | |
| DM | 2025-03-05 | 2025-03-03+ | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $242.94 | -2,755 | 13.9K | -17% | -$669.3K |
| D | 2025-03-05 | 2025-03-03 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +3,871 | 16.3K | +31% | $0 |
| M | 2025-03-03 | 2025-02-28 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $241.69 | -496 | 12.8K | -4% | -$119.9K |
| M | 2025-02-18 | 2025-02-14+ | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $252.71 | -2,103 | 13.0K | -14% | -$531.4K |
| 2025-02-18 | 2025-02-13 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +2,103 | 15.0K | +16% | $0 | |
| M | 2024-11-27 | 2024-11-26+ | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $251.65 | -3,000 | 15.9K | -16% | -$754.9K |
| 2024-11-27 | 2024-11-25 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +3,000 | 15.9K | +23% | $0 | |
| DM | 2024-08-14 | 2024-08-12 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale+OE | $270.99 | -22.0K | 13.0K | -63% | -$5.97M |
| DM | 2024-08-14 | 2024-08-12 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | M - OptEx | $89.09 | +20.7K | 34.9K | +146% | +$1.85M |
| M | 2024-06-26 | 2024-06-25 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $230.99 | -1,198 | 15.3K | -7% | -$276.7K |
| 2024-06-26 | 2024-06-24 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +2,498 | 15.4K | +19% | $0 |
Purchase Sale Sale after option exercise All abbreviations